Phase II, randomized, open-label, global, multicenter study of MEDI4736 monotherapy, Tremelimumab monotherapy, and MEDI4736 in combination with Tremelimumab in patients with recurrent or metastatic squamous cell carcinoma of the head and neck
COMMERCIAL CLINICAL TRIAL
Clinical trial information
- Promoter: ASTRAZENECA FARMACEUTICA ESPAÑA SA
- Phase: II
- Execution start: 15/12/2015
- End of execution: 28/02/2018
- PI: JOAQUINA MARTINEZ GALAN